Overview:

• AstraZeneca: Stronger growth, oncology momentum, and deeper AI use support its innovation-led investment case.

• GSK: Higher income, solid specialty medicine growth, and pipeline expansion create a value-focused opportunity.

• AI Strategy: Both companies use AI for drug discovery, but AstraZeneca currently has the broader AI footprint.

AstraZeneca and GSK now offer two completely different ways to invest in the future of healthcare. The former has a faster growth profile, a large oncology business, a broad drug pipeline, and a deep AI strategy. GSK, on the other hand, has a stronger income case, lower expectations, major vaccine and HIV businesses, and a large effort to rebuild its drug pipeline. The key question now is which company can utilize AI to produce better drugs, stronger sales, and higher profits.

AstraZeneca has a Stronger Growth Profile

AstraZeneca entered the second half of 2026 with strong financial momentum. The company reported USD 30.7 billion in first-half revenue, up 6% at constant exchange rates. Core earnings per share rose 11%. Oncology remained the main source of growth, with USD 14.1 billion in first-half revenue, up 15%. Rare disease revenue also rose 11%.

This performance gives AstraZeneca a clear advantage for investors who want long-term growth. The company aims for USD 80 billion in total revenue by 2030, compared with USD 58.7 billion in 2025. Its pipeline has 183 projects, with 21 late-stage new molecular entities.

The share price tells a different story. AstraZeneca closed at about POUND 119.62 on October 7, 2026, around 6.4% below its level from a year earlier and about 24% below its 52-week high of POUND 157.32. The decline creates a more interesting entry point, although the stock still carries high expectations for its pipeline.

AI Gives AstraZeneca Another Advantage

AstraZeneca has placed AI close to the center of its research strategy. More than 90% of its small-molecule discovery pipeline now has AI support, while more than 600 data science and AI specialists work across its research operation.

The company also uses its MILTON AI system to study health data and identify more than 1,000 diseases that could show signs 10 to 15 years before clinical diagnosis. AstraZeneca has also signed a three-year deal with Owkin for specialized AI agents and expanded genomic data work with Helix.

The value of this strategy goes far beyond office automation. AI can help researchers find drug targets, assess molecules, study patient data, and improve trial design. A better research process can raise the odds of a successful medicine. That matters in an industry where a failed late-stage drug can cost billions of dollars.

Also Read - How Medical Industry is Scaling AI in Healthcare

GSK Offers a Different Investment Case

GSK has a slower growth profile, but its recent results show clear progress. Second-quarter sales rose 5% to POUND 8.4 billion. Specialty Medicines sales rose 14%, oncology sales climbed 17%, HIV sales increased 10%, and vaccines rose 8%. Core operating profit rose 7%, while core earnings per share gained 9%.

GSK also plans more than 20 Phase III trial starts in 2026, compared with an earlier goal of 10. The company has 62 clinical-development assets and has moved seven assets across 18 indications into faster development paths.

That pipeline effort matters for GSK. The company faces future pressure from patent expiry, especially around dolutegravir during the 2028 to 2030 period. Stronger research output could help fill that gap.

GSK Also has a Serious AI Strategy 

GSK does not match AstraZeneca's scale of AI use, but its approach has a clear purpose. The company works with Cerebras on AI analysis of large epigenomic datasets. GSK sees human genetics as a powerful tool for drug discovery and says genetically validated targets have about twice the chance of success.

GSK also signed a research deal with Relation Therapeutics worth up to USD 110 million. The deal focuses on human-cell data and AI models that can help identify new drug targets.

That strategy fits GSK's biggest need. The company already has major commercial businesses. Its challenge lies in creating enough new medicines to support future growth. Better target selection could help improve the value of its research budget.

Also Read - Why Healthcare Needs to Prep Now for Autonomous AI Agents

The Choice Comes Down to Growth or Value

AstraZeneca looks stronger for investors who want growth and exposure to advanced drug discovery. Its oncology franchise, rare disease business, broad pipeline, and deep AI investment create a powerful combination.

GSK offers a different mix. The stock provides substantial cash generation, a prospective 2026 dividend of 69.3 pence, and a share price near POUND 17.91. That dividend implies a yield of about 3.9%. GSK also has room for a stronger valuation if its pipeline delivers better results.

The next major test arrives in late October. GSK reports third-quarter results on October 28, followed by AstraZeneca on October 30. Those reports should offer a clearer view of sales growth, pipeline progress, and management confidence.

For AI-driven healthcare, AstraZeneca holds a stronger position today. GSK, however, could offer greater value if its pipeline strategy starts to produce a steady stream of successful medicines. However, the difference matters. AstraZeneca already has a powerful growth engine, while GSK needs its research investments to create the next stage of that engine.

FAQs

1. Which stock has stronger growth potential, AstraZeneca or GSK?

AstraZeneca has the stronger growth profile, supported by oncology, rare disease, and its large drug pipeline.

2. Which company has the stronger AI strategy?

AstraZeneca currently has the more advanced AI strategy, with more than 90% of its small-molecule discovery pipeline supported by AI.

3. Does GSK offer a higher dividend?

GSK offers a stronger income case, with a prospective 2026 dividend of 69.3 pence and a yield of about 3.9% at the cited share price.

4. What is AstraZeneca's biggest growth area?

Oncology remains AstraZeneca's biggest growth engine, with first-half 2026 revenue of $14.1 billion, up 15%.

5. When are the next major results?

GSK plans to report third-quarter results on October 28, 2026, while AstraZeneca plans to report on October 30, 2026.